Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Obesity (Silver Spring). 2020 Jul;28(7):1254–1262. doi: 10.1002/oby.22854

Figure 2. Effects of empagliflozin treatment on weight, glycosylated hemoglobin, systolic blood pressure, and glucagon.

Figure 2.

Empagliflozin significantly reduced hemoglobin A1c and systolic blood pressure with a non-significant trend toward greater body weight loss. There was no significant treatment-effect on plasma glucagon levels.